Vendor Intelligence Report: Zztai Peptide

Published 13 Jun 2026. 25-page investigative report on who is behind Zztai Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Zztai Peptide is a narrow, uneven test story, not a blanket verdict. Across 31 Finnrick lab tests, the record is 24 pass / 7 fail, for a 77% overall pass rate. Retatrutide is the stronger tested product; Tirzepatide is materially weaker and carries the fill-accuracy concern, with one result severe enough to make label-based dosing assumptions part of the risk discussion.

The corporate record raises a separate continuity issue. Zztai presents as a Hong Kong/Shenzhen/Guangdong-facing peptide supplier, but the evidence centers on a newer Henan operating company, a Shopify storefront first visible in late 2024, and Chinese registry material showing a very thin entity with a simple-cancellation flag while sales channels remain active.

The manufacturing and governance picture is weaker than the storefront claims. The About Us facility image appears to be generic stock photography, third-party listings conflict over whether the business is a manufacturer or trader, and live policy pages include a hair-products shipping sentence, a blank return-address placeholder, and a blank operator field. Public reputation evidence is thin and mixed: Snowy appears in forum and Reddit complaints, but the lab record remains the stronger guide.

For buyers already considering Zztai, the practical split is simple: Retatrutide is the more defensible Zztai choice on current Finnrick data; Tirzepatide requires heightened caution or fresh independent verification. The full report shows the product-level breakdown, ownership trail, and exact documents behind the continuity and policy findings.

Inside the full report:

  • Per-product pass/fail rates, fill-accuracy notes, and methodology-divergence charts for both tested products
  • Tianyancha, WHOIS, Made-in-China, and Wayback captures tying the storefront to the Henan operator
  • Corporate-continuity analysis of the simple-cancellation registry flag
  • Policy-page exhibits showing the hair-template shipping language, placeholder refund address, and blank ToS operator field
  • Facility-claim review including stock-photo analysis and manufacturer/trader listing conflict
  • Sales-persona and reputation review covering Snowy, MillerZZTAI, Reddit, GLP1 Forum, and X promotion signals

Risk assessment

  • Entity-continuity risk — high: Henan Zhitai Technology’s Tianyancha profile shows a 简易注销 simple-cancellation flag while the storefront remains active.
  • Tirzepatide fill-accuracy risk — high: Finnrick field notes identified a Tirzepatide vial labeled 15 mg that tested at 22.3 mg, a +48.7% overfill.
  • Manufacturing-transparency risk — medium: Zztai presents factory-scale supplier signals, but registry and listing evidence show 0 employees, RMB 4,000 paid-in capital, stock facility imagery, and manufacturer/trader inconsistencies.
  • Customer-remedy governance risk — medium: Shipping, refund, and terms pages contain hair-template language, a blank return-address placeholder, and a blank operator field.